<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput xmlns:ns2="local" hits="20" offset="0" totalResults="54"><SearchResults><Drug id="97320" name="OTL-300" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>IRCCS San Raffaele</CompanyOriginator><CompaniesPrimary><Company>Orchard Therapeutics Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Beta thalassemia</Indication></IndicationsPrimary><ActionsPrimary><Action>HBB gene stimulator</Action></ActionsPrimary><Technologies><Technology>Autologous stem cell therapy</Technology><Technology>Biological therapeutic</Technology><Technology>Haematopoietic stem cell therapy</Technology><Technology>Local formulation unspecified</Technology><Technology>Parenteral formulation unspecified</Technology></Technologies><Summary>Orchard Therapeutics , under license from GlaxoSmithKline (GSK, which licensed the program from IRCCS San Raffaele and Fondazione Telethon , through the joint venture San Raffaele Telethon Institute for Gene Therapy ), is developing OTL-300 (GSK-2696277; OLT-300), an ex vivo gene therapy consisting of autologous CD34+ hematopoietic stem/progenitor cells genetically engineered (using a lentiviral vector, GLOBE), to express the human beta globin (HBB), for the potential intraosseous treatment of</Summary><CompaniesSecondary><Company>Fondazione Telethon</Company><Company>GlaxoSmithKline plc</Company><Company>IRCCS San Raffaele</Company><Company>MolMed SpA</Company><Company>San Raffaele Telethon Institute for Gene Therapy</Company></CompaniesSecondary><ActionsSecondary><Action>Blood system agent</Action><Action>Genetically engineered autologous cell therapy</Action></ActionsSecondary><AddedDate>2015-06-18T00:00:00Z</AddedDate></Drug><Drug id="93164" name="lumasiran" lastModificationDate="2019-06-28T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Alnylam Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Alnylam Pharmaceuticals Inc</Company><Company>Medison Pharma Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Hyperoxaluria</Indication></IndicationsPrimary><ActionsPrimary><Action>Hydroxyacid oxidase 1 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide</Technology><Technology>Oligonucleotide conjugated</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>Alnylam Pharmaceuticals is developing lumasiran (ALN-GO1), a siRNA therapy targeting hydroxyacid oxidase (glycolate oxidase) 1 (HAO1; GO1), delivered using an enhanced stabilization chemistry (ESC)-GalNAc conjugate delivery approach, for the potential treatment of primary hyperoxaluria type 1 (PH1) [ 1602090 ], [ 2005759 ]. In September 2018, a phase III trial (ILLUMINATE-A) was initiated for in children aged 6 years and older and adults with PH1 [ 2075807 ]. In May 2018, an NDA submission was</Summary><ActionsSecondary><Action>siRNA agent</Action></ActionsSecondary><AddedDate>2014-10-15T00:00:00Z</AddedDate></Drug><Drug id="92429" name="lisocabtagene maraleucel" lastModificationDate="2019-06-20T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Juno Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Celgene Corp</Company><Company>Juno Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation><RegulatoryDesignation>Regenerative Medicine Advanced Therapy</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>B-cell acute lymphoblastic leukemia</Indication><Indication>B-cell lymphoma</Indication><Indication>Chronic lymphocytic leukemia</Indication><Indication>Diffuse large B-cell lymphoma</Indication><Indication>Follicle center lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action>B-lymphocyte antigen CD19 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric antigen receptor T cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Receptor chimeric</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>Celgene and its wholly owned subsidiary Juno Therapeutics are developing lisocabtagene maraleucel (liso-cel; JCAR-017), comprising autologous T-cells genetically engineered (via a lentiviral vector) to express an anti-CD19 chimeric antigen receptor (CAR), for the potential treatment of B-cell malignancies, primarily non-Hodgkin's lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL),Â follicular lymphoma, mantle cell lymphoma and primary mediastinal large B-cell lymphoma [ 1588211 ], [ 1588544</Summary><IndicationsSecondary><Indication>Leukemia</Indication><Indication>Non-Hodgkin lymphoma</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2014-08-28T00:00:00Z</AddedDate></Drug><Drug id="92166" name="rVSV-EBOV" lastModificationDate="2019-06-21T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Public Health Agency of Canada</CompanyOriginator><CompaniesPrimary><Company>Merck &amp; Co Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Ebola virus infection</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Glycoprotein</Technology><Technology>Intramuscular formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>Merck &amp;amp; Co , under license from NewLink Genetics ' subsidiary BioProtection Systems (BPS) (originally under license from the Public Health Agency of Canada (PHAC)), is developing rVSV-EBOV (V-920; BPSC-1001; rVSV-ZEBOV-GP; VSV-EBOV; VSV-G-ZEBOV; VSV-DG-ZEBOV; rVSV-DG-ZEBOV-GP), a monovalent recombinant vesicular stomatitis virus (rVSV) vaccine for the potential prevention of Ebola virus infection [ 1582913 ], [ 1610853 ], [ 1610855 ], [ 1615221 ], [ 1639598 ]. In May 2017, the Democratic</Summary><CompaniesSecondary><Company>BioProtection Systems Corp</Company><Company>Public Health Agency of Canada</Company></CompaniesSecondary><ActionsSecondary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action><Action>Recombinant viral vector vaccine</Action></ActionsSecondary><AddedDate>2014-08-06T00:00:00Z</AddedDate></Drug><Drug id="90321" name="nangibotide" lastModificationDate="2018-10-09T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Inotrem SA</CompanyOriginator><CompaniesPrimary><Company>Inotrem SA</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Myocardial infarction</Indication><Indication>Septic shock</Indication></IndicationsPrimary><ActionsPrimary><Action>TREM receptor 1 antagonist</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Peptide</Technology></Technologies><Summary>Inotrem is developing the peptide nangibotide (LR-12; Motrem; CardioTREM), a triggering receptor expressed on myeloid cells 1 (TREM-1) inhibitor, for the potential iv treatment of sepsis and septic shock (as Motrem) [ 1534885 ], [ 1795904 ], [ 1980588 ]. The company is also developing nangibotide for the potential treatment of acute myocardial infarction (as CardioTREM) [ 1970676 ]. In July 2017, a phase II trial was initiated in patients with septic shock [ 1931536 ]; in September 2018, positive</Summary><IndicationsSecondary><Indication>Sepsis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Cardioprotectant</Action></ActionsSecondary><AddedDate>2014-03-14T00:00:00Z</AddedDate></Drug><Drug id="89744" name="MTBVAC" lastModificationDate="2019-02-19T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Universidad de Zaragoza</CompanyOriginator><CompaniesPrimary><Company>Biofabri SL</Company><Company>International AIDS Vaccine Initiative</Company><Company>Universidad de Zaragoza</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Mycobacterium tuberculosis infection</Indication></IndicationsPrimary><Technologies><Technology>Bacteria recombinant</Technology><Technology>Biological therapeutic</Technology><Technology>Intradermal formulation</Technology></Technologies><Summary>Biofabri , in collaboration with University of Zaragoza , is developing MTBVAC (MTBVAC-01), a genetically modified live attenuated bacterial vaccine, administered intradermally for the potential prevention of human tuberculosis [ 1497758 ], [ 1516799 ], [ 1516774 ], [ 1573984 ]. In February 2019, a phase IIa study was initiated in South African neonates with tuberculosis [ 2120599 ]. In April 2016, a phase I/II trial was initiated in South Africa in newborns with tuberculosis; the study completed</Summary><CompaniesSecondary><Company>Aeras Global TB Vaccine Foundation</Company></CompaniesSecondary><ActionsSecondary><Action>Live attenuated bacterial vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondary><AddedDate>2014-01-23T00:00:00Z</AddedDate></Drug><Drug id="89200" name="GSK-2857916" lastModificationDate="2019-07-02T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>GlaxoSmithKline plc</CompanyOriginator><CompaniesPrimary><Company>Dana-Farber Cancer Institute Inc</Company><Company>GlaxoSmithKline plc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Multiple myeloma</Indication></IndicationsPrimary><ActionsPrimary><Action>APRIL receptor modulator</Action></ActionsPrimary><Technologies><Technology>Antibody drug conjugate</Technology><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody conjugated</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><Summary>GlaxoSmithKline (GSK), in collaboration with Dana-Farber Cancer Institute , is developing belantamab mafodotin (GSK-2857916; GSK'916; J6M0-mcMMAF), a humanized Fc-engineered anti-B cell maturation antigen (BCMA) antibody drug conjugate (ADC) conjugated to microtubule-disrupting agent monomethyl auristatin F (MMAF) via a protease-resistant maleimidocaproyl linker and afucosylated to enhance ADCC using Seattle Genetics ' ADC technology, for the potential treatment of multiple myeloma (MM) [ 1529458</Summary><ActionsSecondary><Action>Anticancer monoclonal antibody</Action><Action>Immunotoxin</Action><Action>Microtubule modulator</Action></ActionsSecondary><AddedDate>2013-12-17T00:00:00Z</AddedDate></Drug><Drug id="88038" name="onasemnogene abeparvovec" lastModificationDate="2019-07-02T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Nationwide Children's Hospital</CompanyOriginator><CompaniesPrimary><Company>AveXis Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation><RegulatoryDesignation>Sakigake</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Spinal muscular atrophy</Indication></IndicationsPrimary><ActionsPrimary><Action>SMN1 gene stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intrathecal formulation</Technology><Technology>Intravenous formulation</Technology><Technology>Suspension</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>AveXis (a wholly owned subsidiary of Novartis ), a spin-out from BioLife Cell Bank, under license from the Nationwide Children's Hospital and Ohio State University , has developed and launched onasemnogene abeparvovec (AVXS-101; scAAV9.CB.SMN; chariSMA, onasemnogene abeparvovec-xioi; Zolgensma), an adeno-associated virus (AAV) serotype 9 vector-based gene therapy containing cDNA of the survival motor neuron 1 (SMN1) gene under the control of the hybrid CMV enhancer/chicken beta-actin promoter</Summary><CompaniesSecondary><Company>Nationwide Children's Hospital</Company><Company>Ohio State University</Company></CompaniesSecondary><ActionsSecondary><Action>Adeno-associated virus based gene therapy</Action></ActionsSecondary><AddedDate>2013-10-18T00:00:00Z</AddedDate></Drug><Drug id="86450" name="AT-132, Audentes" lastModificationDate="2019-05-13T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Audentes Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Audentes Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation><RegulatoryDesignation>Regenerative Medicine Advanced Therapy</RegulatoryDesignation><RegulatoryDesignation>Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Myopathy</Indication></IndicationsPrimary><ActionsPrimary><Action>MTM1 gene stimulator</Action><Action>Myotubularin stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intravenous formulation</Technology><Technology>Oligonucleotide</Technology><Technology>Parenteral formulation unspecified</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>Audentes Therapeutics is developing resamirigene bilparvovec (AT-132, previously AT-001), a recombinant adeno-associated viral (AAV) vector-8-based gene therapy encoded with MTM1 gene expressing myotubularin, using NAV vector technology from RegenX Biosciences , for the potential treatment of X-linked myotubular myopathy (XLMTM) [ 1454102 ], [ 1454070 ], [ 1458418 ], [ 1463932 ], [ 1521815 ], [ 1724870 ], [ 1990300 ]. In July 2016, a phase I/II study was initiated [ 1788800 ], [ 1789177</Summary><ActionsSecondary><Action>Adeno-associated virus based gene therapy</Action></ActionsSecondary><AddedDate>2013-07-19T00:00:00Z</AddedDate></Drug><Drug id="84625" name="voxelotor" lastModificationDate="2019-06-20T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Global Blood Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>Global Blood Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation><RegulatoryDesignation>Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Sickle cell anemia</Indication></IndicationsPrimary><ActionsPrimary><Action>Hemoglobin alpha subunit modulator</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Global Blood Therapeutics (GBT) is developing voxelotor (GBT-440, GTx-011), which binds the hemoglobin alpha-chain increasing hemoglobin's affinity for oxygen and preventing abnormal hemoglobin polymer formation, using its SHAPE platform, for the potential oral once-daily prophylactic treatment of sickle cell disease (SCD) [ 1405829 ], [ 1405876 ], [ 1507409 ], [ 1504949 ], [ 1610896 ], [ 1619448 ], [ 1712057 ], [ 1774335 ], [ 1931154 ], [ 2011705 ]. In December 2016, a phase III trial (HOPE) was</Summary><IndicationsSecondary><Indication>Idiopathic pulmonary fibrosis</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Blood system agent</Action></ActionsSecondary><AddedDate>2013-04-18T00:00:00Z</AddedDate></Drug><Drug id="84386" name="RG-6042" lastModificationDate="2019-07-03T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Ionis Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Chugai Pharmaceutical Co Ltd</Company><Company>Roche Holding AG</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Huntingtons chorea</Indication></IndicationsPrimary><ActionsPrimary><Action>HTT gene inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intrathecal formulation</Technology><Technology>Oligonucleotide antisense</Technology><Technology>RNA antisense</Technology></Technologies><Summary>Roche and Chugai , under license from Ionis Pharmaceuticals (formerly Isis Pharmaceuticals), are developing RG-6042 (HTT-ASO; IONIS-HTTRx; RO-7234292; ISIS-HTTRx; ISIS-443139), an antisense oligonucleotide (ASO) that silences huntingtin (HTT) mRNA and blocks all forms of the huntingtin protein, using Isis' ASO technology, for the potential intrathecal treatment of Huntington's disease (HD) [ 1990699 ], [ 1992162 ], [ 2009686 ], [ 2062833 ]. In January 2019, a phase III trial was initiated in</Summary><CompaniesSecondary><Company>Ionis Pharmaceuticals Inc</Company></CompaniesSecondary><ActionsSecondary><Action>Antisense oligonucleotide inhibitor</Action><Action>Neuroprotectant</Action></ActionsSecondary><AddedDate>2013-04-09T00:00:00Z</AddedDate></Drug><Drug id="84060" name="idecabtagene vicleucel" lastModificationDate="2019-05-27T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>bluebird bio Inc</CompanyOriginator><CompaniesPrimary><Company>Celgene Corp</Company><Company>bluebird bio Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Multiple myeloma</Indication></IndicationsPrimary><ActionsPrimary><Action>APRIL receptor modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric antigen receptor T cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Receptor chimeric</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>bluebird bio and licensee Celgene are developing idecabtagene vicleucel (ide-cel, bb-2121), comprising autologous T cells genetically engineered (via lentiviral vector) to express an anti-BCMA (B-cell maturation antigen) chimeric antigen receptor (CAR) with 4-1BB and CD3-zeta intracellular signaling domains, for the potential iv treatment of hematological malignancies, in particular multiple myeloma (MM) [ 1911564 ], [ 1911738 ], [ 2147829 ]. In October 2018, a phase III trial (KarMMa-3) in</Summary><IndicationsSecondary><Indication>Cancer</Indication><Indication>Hematological neoplasm</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2013-03-22T00:00:00Z</AddedDate></Drug><Drug id="82693" name="givosiran" lastModificationDate="2019-07-03T00:00:00Z" phaseHighest="Pre-registration"><CompanyOriginator>Alnylam Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company>Alnylam Pharmaceuticals Inc</Company><Company>Medison Pharma Ltd</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Acute intermittent porphyria</Indication><Indication>Hepatic porphyria</Indication></IndicationsPrimary><ActionsPrimary><Action>5 Aminolevulinate synthase 1 inhibitor</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Oligonucleotide</Technology><Technology>Subcutaneous formulation</Technology></Technologies><Summary>Alnylam Pharmaceuticals is developing givosiran (ALN-AS1), an RNAi therapeutic targeting aminolevulinate synthase 1 (ALAS-1), using its GalNAc-siRNA conjugate technology, for the potential treatment and prevention of acute hepatic porphyrias (AHP), including acute intermittent porphyria (AIP) [ 1354589 ], [ 1354745 ], [ 1905413 ]. In late 2018, a rolling NDA submission was initiated for the treatment of AHP [ 2120024 ]; in June 2019, the rolling NDA submission for the treatment of AHP was completed</Summary><ActionsSecondary><Action>siRNA agent</Action></ActionsSecondary><AddedDate>2013-01-07T00:00:00Z</AddedDate></Drug><Drug id="81474" name="axicabtagene ciloleucel" lastModificationDate="2019-07-03T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Cabaret Biotech Ltd</CompanyOriginator><CompaniesPrimary><Company>Daiichi Sankyo Co Ltd</Company><Company>Fosun Kite</Company><Company>Kite Pharma Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Acute lymphoblastic leukemia</Indication><Indication>B-cell lymphoma</Indication><Indication>Chronic lymphocytic leukemia</Indication><Indication>Diffuse large B-cell lymphoma</Indication><Indication>Follicle center lymphoma</Indication><Indication>High grade B-cell lymphoma</Indication><Indication>Leukemia</Indication><Indication>Mantle cell lymphoma</Indication><Indication>Non-Hodgkin lymphoma</Indication><Indication>Primary mediastinal large B-cell lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action>B-lymphocyte antigen CD19 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric antigen receptor T cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Receptor chimeric</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>Kite Pharma , a subsidiary of Gilead Sciences , under license from Cabaret Biotech , has developed and launched axicabtagene ciloleucel (Yescarta; KTE-C19, FKC-876; KTE-X19), which comprises autologous T cells genetically engineered (using a retroviral vector) to express an anti-CD19 chimeric antigen receptor (CAR) [ 1717904 ]. In the US, the product is indicated for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy</Summary><CompaniesSecondary><Company>Cabaret Biotech Ltd</Company><Company>Shanghai Fosun Pharmaceutical (Group) Co Ltd</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2012-10-17T00:00:00Z</AddedDate></Drug><Drug id="79749" name="tisagenlecleucel" lastModificationDate="2019-07-01T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>Abramson Cancer Center of the University of Pennsylvania</CompanyOriginator><CompaniesPrimary><Company>Abramson Cancer Center of the University of Pennsylvania</Company><Company>Novartis AG</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Accelerated Approval</RegulatoryDesignation><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>B-cell acute lymphoblastic leukemia</Indication><Indication>Chronic lymphocytic leukemia</Indication><Indication>Diffuse large B-cell lymphoma</Indication><Indication>Follicle center lymphoma</Indication><Indication>Hodgkins disease</Indication><Indication>Multiple myeloma</Indication><Indication>Non-Hodgkin lymphoma</Indication></IndicationsPrimary><ActionsPrimary><Action>B-lymphocyte antigen CD19 modulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Chimeric antigen receptor T cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Protein fusion</Technology><Technology>Receptor chimeric</Technology><Technology>Suspension</Technology><Technology>T-lymphocyte</Technology></Technologies><Summary>Novartis , under license from the Abramson Cancer Center of the University of Pennsylvania , has developed and launched tisagenlecleucel-T (CTL-019, previously CART-19; Kymriah), which comprises autologous T-cells genetically engineered (via lentivirus) to express a murine-derived anti-CD19 chimeric antigen receptor (CAR) [ 1739632 ], [ 1957480 ]. The product is indicated in the US for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (B-cell ALL) that</Summary><IndicationsSecondary><Indication>B-cell lymphoma</Indication><Indication>Leukemia</Indication><Indication>Mantle cell lymphoma</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Genetically engineered autologous cell therapy</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2012-07-27T00:00:00Z</AddedDate></Drug><Drug id="78821" name="odevixibat" lastModificationDate="2019-07-01T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Albireo Ltd</CompanyOriginator><CompaniesPrimary><Company>Albireo Pharma Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation><RegulatoryDesignation>Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Alagille syndrome</Indication><Indication>Biliary atresia</Indication><Indication>Non-alcoholic steatohepatitis</Indication><Indication>Primary biliary cholangitis</Indication><Indication>Progressive familial intrahepatic cholestasis</Indication><Indication>Pruritus</Indication></IndicationsPrimary><ActionsPrimary><Action>Ileal sodium bile acid cotransporter inhibitor</Action></ActionsPrimary><Technologies><Technology>Capsule formulation</Technology><Technology>Local formulation unspecified</Technology><Technology>Oral formulation</Technology><Technology>Radiolabeling</Technology><Technology>Small molecule therapeutic</Technology></Technologies><Summary>Albireo Pharma , following the merger of Albireo Ltd and Biodel, is developing odevixibat (A-4250) the lead and a specialized formulation from a program of ileal bile acid transporter (IBAT) inhibitors, for the potential treatment of liver dieases, including progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), non-alcoholic steatohepatitis (NASH), and cholestatic pruritus [ 1716688 ], [ 1302032 ], [ 1302596 ], [ 1310402 ], [ 1410973 ], [ 1605500 ], [ 1704309 ], [ 1869780</Summary><CompaniesSecondary><Company>Albireo Ltd</Company></CompaniesSecondary><IndicationsSecondary><Indication>Liver disease</Indication></IndicationsSecondary><ActionsSecondary><Action>Anti-inflammatory</Action><Action>Topical antipruritic product</Action></ActionsSecondary><AddedDate>2012-06-20T00:00:00Z</AddedDate></Drug><Drug id="78095" name="valoctocogene roxaparvovec" lastModificationDate="2019-06-07T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>University College London</CompanyOriginator><CompaniesPrimary><Company>BioMarin Pharmaceutical Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Paediatric Investigation Plan</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Factor VIII deficiency</Indication></IndicationsPrimary><ActionsPrimary><Action>F8 gene stimulator</Action></ActionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>BioMarin Pharmaceutical , under license from University College London (UCL) andÂ  St Jude Children's Research Hospital , is developing valoctocogene roxaparvovec (BMN-270), an AAV5-based gene therapy encoding a B-domain deleted (BDD) SQ variant of human factor VIII (hFVIII) gene under the control of a hybrid liver-specific promoter (HLP), which uses AAV-FVIII technology acquired from UCL and St Jude Children's Research Hospital, for the potential iv treatment of hemophilia A [ 1292251 ], [ 1385532</Summary><CompaniesSecondary><Company>St Jude Children's Research Hospital</Company><Company>University College London</Company></CompaniesSecondary><ActionsSecondary><Action>Adeno-associated virus based gene therapy</Action></ActionsSecondary><AddedDate>2012-05-21T00:00:00Z</AddedDate></Drug><Drug id="75100" name="MV-CHIK" lastModificationDate="2019-06-05T00:00:00Z" phaseHighest="Phase 2 Clinical"><CompanyOriginator>Themis Bioscience GmbH</CompanyOriginator><CompaniesPrimary><Company>Themis Bioscience GmbH</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Chikungunya virus infection</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Intramuscular formulation</Technology><Technology>Virus recombinant</Technology></Technologies><Summary>Themis is developing MV-CHIK, a recombinant live-attenuated Schwarz vaccine strain of measles virus (MV) expressing full subgenomic ORF encoding for the Chikungunya virus capsid and envelope structural proteins from the CHIKV La Reunion Strain-06-46, administered intramuscularly for the potential prevention of Chikungunya virus infection [ 1249706 ], [ 1249714 ] [ 1605066 ], [ 1608316 ], [ 1789962 ]. In July 2016, the vaccine was listed as being in phase II development [ 1779888 ]. In November</Summary><ActionsSecondary><Action>Live attenuated viral vaccine</Action><Action>Prophylactic vaccine</Action></ActionsSecondary><AddedDate>2011-12-21T00:00:00Z</AddedDate></Drug><Drug id="74138" name="brexanolone" lastModificationDate="2019-06-27T00:00:00Z" phaseHighest="Launched"><CompanyOriginator>SAGE Therapeutics Inc</CompanyOriginator><CompaniesPrimary><Company>SAGE Therapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Fast Track</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>Priority Review</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Postnatal depression</Indication></IndicationsPrimary><ActionsPrimary><Action>GABA A receptor modulator</Action></ActionsPrimary><Technologies><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Steroid</Technology></Technologies><Summary>SAGE Therapeutics has developed and launched a proprietary iv formulation of brexanoloneÂ (allopregnanolone; Zulresso; SAGE-547; SGE-102), a naturally occurring neurosteroid and metabolite of progesterone and the lead from an allosteric GABA A receptor modulator program that incorporates CyDex' s (now a subsidiary of Ligand ) Captisol technology [ 1739102 ], [ 1902974 ]. The product is indicated in the US for the treatment of postpartum depression (PPD) in adults [ 2131567 ]. In July 2019, brexanolone</Summary><IndicationsSecondary><Indication>Central nervous system disease</Indication><Indication>Essential tremor</Indication><Indication>Major depressive disorder</Indication><Indication>Status epilepticus</Indication></IndicationsSecondary><ActionsSecondary><Action>Anticonvulsant agent</Action><Action>Antidepressant</Action></ActionsSecondary><AddedDate>2011-10-19T00:00:00Z</AddedDate></Drug><Drug id="73916" name="tabelecleucel" lastModificationDate="2019-06-24T00:00:00Z" phaseHighest="Phase 3 Clinical"><CompanyOriginator>Memorial Sloan-Kettering Cancer Center</CompanyOriginator><CompaniesPrimary><Company>Atara Biotherapeutics Inc</Company></CompaniesPrimary><RegulatoryDesignations><RegulatoryDesignation>Advanced Therapy Medicinal Product</RegulatoryDesignation><RegulatoryDesignation>Breakthrough Therapy</RegulatoryDesignation><RegulatoryDesignation>Orphan Drug</RegulatoryDesignation><RegulatoryDesignation>PRIME</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication>Lymphoproliferative disease</Indication><Indication>Nasopharyngeal carcinoma</Indication><Indication>Post transplant lymphoproliferative disease</Indication></IndicationsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>T-lymphocyte cell therapy</Technology></Technologies><Summary>Atara Biotherapeutics , under license from Memorial Sloan-Kettering Cancer Center (MSKCC), is developing tabelecleucel (EBV-CTL; ATA-129; tab-cel), consisting of allogeneic Epstein-Barr virus(EBV)-specific cytotoxic T lymphocytes (EBV-CTLs), generated by exposing donor T cells to EBV antigens, for the potential iv treatment of EBV-associated lymphoproliferative disease (EBV-LPD), including post-transplant lymphoproliferative disorder (PTLD), and EBV-positive cancers, including nasopharyngeal</Summary><CompaniesSecondary><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesSecondary><ActionsSecondary><Action>Anticancer</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondary><AddedDate>2011-10-06T00:00:00Z</AddedDate></Drug></SearchResults><Filters total="15"><Filter label="Drug Sales 2010 (USD M)" name="drugSalesYearActual" total="5"><FilterOption count="28" label="&lt; 100"></FilterOption><FilterOption count="0" label="â¥ 100 and  250"></FilterOption><FilterOption count="0" label="â¥ 250 and  500"></FilterOption><FilterOption count="0" label="â¥ 500 and  1000"></FilterOption><FilterOption count="0" label="â¥ 1000"></FilterOption></Filter><Filter label="Secondary Actions" name="actionsSecondary" total="48"><FilterOption id="1545" count="13" label="Anticancer"></FilterOption><FilterOption id="4790" count="10" label="Genetically engineered autologous cell therapy"></FilterOption><FilterOption id="393" count="10" label="Immunostimulant"></FilterOption><FilterOption id="2953" count="8" label="Anti-inflammatory"></FilterOption><FilterOption id="7761" count="8" label="T-lymphocyte stimulator"></FilterOption><FilterOption id="4781" count="7" label="Adeno-associated virus based gene therapy"></FilterOption><FilterOption id="12378" count="4" label="Prophylactic vaccine"></FilterOption><FilterOption id="991" count="3" label="Antiviral"></FilterOption><FilterOption id="1615" count="3" label="Neuroprotectant"></FilterOption><FilterOption id="55685" count="2" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="2941" count="2" label="Antidepressant"></FilterOption><FilterOption id="1546" count="2" label="Blood system agent"></FilterOption><FilterOption id="968" count="2" label="Coagulation stimulator"></FilterOption><FilterOption id="399" count="2" label="Hypoglycemic agent"></FilterOption><FilterOption id="1596" count="2" label="Immunomodulator"></FilterOption><FilterOption id="396" count="2" label="Immunosuppressant"></FilterOption><FilterOption id="539" count="2" label="Immunotoxin"></FilterOption><FilterOption id="12364" count="2" label="Live attenuated viral vaccine"></FilterOption><FilterOption id="4782" count="2" label="Retrovirus based gene therapy"></FilterOption><FilterOption id="26035" count="2" label="siRNA agent"></FilterOption><FilterOption id="59620" count="2" label="Unspecified drug target"></FilterOption><FilterOption id="1586" count="1" label="Anticancer chemosensitizer"></FilterOption><FilterOption id="62255" count="1" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="70" count="1" label="Anticonvulsant agent"></FilterOption><FilterOption id="7294" count="1" label="Antisense oligonucleotide inhibitor"></FilterOption><FilterOption id="1590" count="1" label="Apoptosis inhibitor"></FilterOption><FilterOption id="1840" count="1" label="Appetite suppressant"></FilterOption><FilterOption id="2659" count="1" label="Cardioprotectant"></FilterOption><FilterOption id="965" count="1" label="Cardiovascular agent"></FilterOption><FilterOption id="767" count="1" label="Cell cycle inhibitor"></FilterOption><FilterOption id="7266" count="1" label="Cerebroprotectant"></FilterOption><FilterOption id="803" count="1" label="DNA modulator"></FilterOption><FilterOption id="52488" count="1" label="DNA replication pathway modulator"></FilterOption><FilterOption id="140" count="1" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="610" count="1" label="Hematopoietic stimulator"></FilterOption><FilterOption id="4784" count="1" label="Herpes virus based gene therapy"></FilterOption><FilterOption id="12367" count="1" label="Inactivated viral vaccine"></FilterOption><FilterOption id="12363" count="1" label="Live attenuated bacterial vaccine"></FilterOption><FilterOption id="2575" count="1" label="Microtubule inhibitor"></FilterOption><FilterOption id="563" count="1" label="Microtubule modulator"></FilterOption><FilterOption id="284" count="1" label="Nootropic agent"></FilterOption><FilterOption id="15128" count="1" label="Ophthalmological agent"></FilterOption><FilterOption id="12370" count="1" label="Recombinant viral vector vaccine"></FilterOption><FilterOption id="172638" count="1" label="SMN2 gene modulator"></FilterOption><FilterOption id="53559" count="1" label="Stem cell stimulator"></FilterOption><FilterOption id="7293" count="1" label="Synergist"></FilterOption><FilterOption id="15180" count="1" label="Topical antipruritic product"></FilterOption><FilterOption id="1720" count="1" label="Virus uptake inhibitor"></FilterOption></Filter><Filter label="Drug Deal Types" name="drugDealTypes" total="17"><FilterOption id="4" count="34" label="Drug - Development/Commercialization License"></FilterOption><FilterOption id="3" count="22" label="Drug - Early Research/Development"></FilterOption><FilterOption id="13" count="22" label="Drug - Funding"></FilterOption><FilterOption id="7" count="17" label="Drug - Development Services"></FilterOption><FilterOption id="11" count="14" label="Patent - Exclusive Rights"></FilterOption><FilterOption id="6" count="13" label="Drug - Manufacturing/Supply"></FilterOption><FilterOption id="10" count="13" label="Technology - Other Proprietary"></FilterOption><FilterOption id="8" count="7" label="Technology - Delivery/Formulation"></FilterOption><FilterOption id="14" count="5" label="Drug - Asset Divestment"></FilterOption><FilterOption id="2" count="5" label="Drug - Screening/Evaluation"></FilterOption><FilterOption id="5" count="4" label="Drug - Commercialization License"></FilterOption><FilterOption id="19" count="2" label="Company - Joint Venture"></FilterOption><FilterOption id="20" count="2" label="Company - M&amp;A (in whole or part)"></FilterOption><FilterOption id="15" count="2" label="Drug - CRADA"></FilterOption><FilterOption id="12" count="2" label="Patent - Non-Exclusive Rights"></FilterOption><FilterOption id="1" count="1" label="Drug - Discovery/Design"></FilterOption><FilterOption id="9" count="1" label="Technology - Target Validation"></FilterOption></Filter><Filter label="Drug Forecast 2015 (USD M)" name="drugSalesYearEstimate" total="5"><FilterOption count="17" label="&lt; 100"></FilterOption><FilterOption count="3" label="â¥ 100 and  250"></FilterOption><FilterOption count="1" label="â¥ 250 and  500"></FilterOption><FilterOption count="2" label="â¥ 500 and  1000"></FilterOption><FilterOption count="0" label="â¥ 1000"></FilterOption></Filter><Filter label="Drug Deals Count" name="drugDealsCount" total="8"><FilterOption count="3" label="= 0"></FilterOption><FilterOption count="8" label="&gt; 1 and â¤ 1"></FilterOption><FilterOption count="13" label="&gt; 2 and â¤ 2"></FilterOption><FilterOption count="6" label="&gt; 3 and â¤ 3"></FilterOption><FilterOption count="4" label="&gt; 4 and â¤ 4"></FilterOption><FilterOption count="2" label="&gt; 5 and â¤ 5"></FilterOption><FilterOption count="15" label="&gt; 6 and â¤ 10"></FilterOption><FilterOption count="3" label="&gt; 11"></FilterOption></Filter><Filter label="Technologies" name="technologies" total="62"><FilterOption id="761" count="43" label="Biological therapeutic"></FilterOption><FilterOption id="648" count="31" label="Intravenous formulation"></FilterOption><FilterOption id="740" count="24" label="Infusion"></FilterOption><FilterOption id="62" count="13" label="Virus recombinant"></FilterOption><FilterOption id="762" count="11" label="Small molecule therapeutic"></FilterOption><FilterOption id="585" count="10" label="Oral formulation"></FilterOption><FilterOption id="84" count="8" label="Protein fusion"></FilterOption><FilterOption id="1263" count="7" label="Immuno-oncology"></FilterOption><FilterOption id="135" count="7" label="T-lymphocyte"></FilterOption><FilterOption id="1247" count="6" label="Chimeric antigen receptor T cell therapy"></FilterOption><FilterOption id="573" count="6" label="Immunoglobulin-G"></FilterOption><FilterOption id="345" count="6" label="Receptor chimeric"></FilterOption><FilterOption id="586" count="5" label="Capsule formulation"></FilterOption><FilterOption id="651" count="5" label="Intramuscular formulation"></FilterOption><FilterOption id="168" count="5" label="Monoclonal antibody human"></FilterOption><FilterOption id="766" count="5" label="Parenteral formulation unspecified"></FilterOption><FilterOption id="647" count="5" label="Subcutaneous formulation"></FilterOption><FilterOption id="884" count="4" label="Haematopoietic stem cell therapy"></FilterOption><FilterOption id="80" count="4" label="Peptide"></FilterOption><FilterOption id="85" count="4" label="Protein recombinant"></FilterOption><FilterOption id="856" count="3" label="Autologous stem cell therapy"></FilterOption><FilterOption id="175" count="3" label="Drug combination"></FilterOption><FilterOption id="103" count="3" label="Oligonucleotide"></FilterOption><FilterOption id="1164" count="2" label="Antibody drug conjugate"></FilterOption><FilterOption id="180" count="2" label="Antibody fragment"></FilterOption><FilterOption id="654" count="2" label="Intrathecal formulation"></FilterOption><FilterOption id="347" count="2" label="Intratumoral formulation"></FilterOption><FilterOption id="764" count="2" label="Local formulation unspecified"></FilterOption><FilterOption id="171" count="2" label="Monoclonal antibody conjugated"></FilterOption><FilterOption id="879" count="2" label="Peripheral blood stem cell therapy"></FilterOption><FilterOption id="901" count="2" label="Recombinant enzyme"></FilterOption><FilterOption id="745" count="2" label="Suspension"></FilterOption><FilterOption id="589" count="2" label="Sustained release formulation"></FilterOption><FilterOption id="1246" count="2" label="T-lymphocyte cell therapy"></FilterOption><FilterOption id="857" count="1" label="Allogenic stem cell therapy"></FilterOption><FilterOption id="56" count="1" label="Bacteria recombinant"></FilterOption><FilterOption id="166" count="1" label="Chimeric monoclonal antibody"></FilterOption><FilterOption id="611" count="1" label="Dermatological formulation"></FilterOption><FilterOption id="775" count="1" label="Dermatological gel formulation"></FilterOption><FilterOption id="1672" count="1" label="Directed prodrug therapy"></FilterOption><FilterOption id="898" count="1" label="Formulation powder"></FilterOption><FilterOption id="750" count="1" label="Freeze drying"></FilterOption><FilterOption id="1671" count="1" label="Gene directed enzyme prodrug therapy"></FilterOption><FilterOption id="74" count="1" label="Glycoprotein"></FilterOption><FilterOption id="596" count="1" label="Injectable formulation"></FilterOption><FilterOption id="851" count="1" label="Intradermal formulation"></FilterOption><FilterOption id="649" count="1" label="Intraperitoneal formulation"></FilterOption><FilterOption id="349" count="1" label="Lipid"></FilterOption><FilterOption id="169" count="1" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="701" count="1" label="Nucleoside synthesis"></FilterOption><FilterOption id="102" count="1" label="Nucleotide and derivatives"></FilterOption><FilterOption id="569" count="1" label="Oligonucleotide antisense"></FilterOption><FilterOption id="262" count="1" label="Oligonucleotide conjugated"></FilterOption><FilterOption id="620" count="1" label="Ophthalmic formulation"></FilterOption><FilterOption id="660" count="1" label="Oral sustained release formulation"></FilterOption><FilterOption id="1652" count="1" label="Prodrug"></FilterOption><FilterOption id="662" count="1" label="Quick release formulation"></FilterOption><FilterOption id="724" count="1" label="Radiolabeling"></FilterOption><FilterOption id="94" count="1" label="RNA antisense"></FilterOption><FilterOption id="746" count="1" label="Solution"></FilterOption><FilterOption id="90" count="1" label="Steroid"></FilterOption><FilterOption id="863" count="1" label="Umbilical cord stem cell therapy"></FilterOption></Filter><Filter label="Drug Added by Day" name="drugAddedDateByDay" total="53"><FilterOption count="1" label="1997-06-26"></FilterOption><FilterOption count="1" label="1999-05-06"></FilterOption><FilterOption count="1" label="2001-06-11"></FilterOption><FilterOption count="1" label="2004-11-22"></FilterOption><FilterOption count="1" label="2005-05-18"></FilterOption><FilterOption count="1" label="2005-06-13"></FilterOption><FilterOption count="1" label="2005-06-29"></FilterOption><FilterOption count="1" label="2006-06-27"></FilterOption><FilterOption count="1" label="2006-12-11"></FilterOption><FilterOption count="1" label="2007-08-06"></FilterOption><FilterOption count="1" label="2008-02-07"></FilterOption><FilterOption count="1" label="2008-04-14"></FilterOption><FilterOption count="1" label="2008-06-11"></FilterOption><FilterOption count="1" label="2008-06-26"></FilterOption><FilterOption count="1" label="2008-08-27"></FilterOption><FilterOption count="1" label="2008-12-01"></FilterOption><FilterOption count="1" label="2009-02-17"></FilterOption><FilterOption count="1" label="2009-04-22"></FilterOption><FilterOption count="1" label="2009-06-09"></FilterOption><FilterOption count="1" label="2009-07-24"></FilterOption><FilterOption count="1" label="2009-12-17"></FilterOption><FilterOption count="1" label="2010-01-18"></FilterOption><FilterOption count="1" label="2011-03-30"></FilterOption><FilterOption count="1" label="2011-06-01"></FilterOption><FilterOption count="1" label="2011-08-04"></FilterOption><FilterOption count="1" label="2011-10-06"></FilterOption><FilterOption count="1" label="2011-10-19"></FilterOption><FilterOption count="1" label="2011-12-21"></FilterOption><FilterOption count="1" label="2012-05-21"></FilterOption><FilterOption count="1" label="2012-06-20"></FilterOption><FilterOption count="1" label="2012-07-27"></FilterOption><FilterOption count="1" label="2012-10-17"></FilterOption><FilterOption count="1" label="2013-01-07"></FilterOption><FilterOption count="1" label="2013-03-22"></FilterOption><FilterOption count="1" label="2013-04-09"></FilterOption><FilterOption count="1" label="2013-04-18"></FilterOption><FilterOption count="1" label="2013-07-19"></FilterOption><FilterOption count="1" label="2013-10-18"></FilterOption><FilterOption count="1" label="2013-12-17"></FilterOption><FilterOption count="1" label="2014-01-23"></FilterOption><FilterOption count="1" label="2014-03-14"></FilterOption><FilterOption count="1" label="2014-08-06"></FilterOption><FilterOption count="1" label="2014-08-28"></FilterOption><FilterOption count="1" label="2014-10-15"></FilterOption><FilterOption count="1" label="2015-06-18"></FilterOption><FilterOption count="1" label="2016-07-18"></FilterOption><FilterOption count="1" label="2016-08-31"></FilterOption><FilterOption count="1" label="2017-01-11"></FilterOption><FilterOption count="1" label="2017-05-29"></FilterOption><FilterOption count="1" label="2017-09-26"></FilterOption><FilterOption count="1" label="2018-01-12"></FilterOption><FilterOption count="1" label="2018-06-21"></FilterOption><FilterOption count="1" label="2018-10-05"></FilterOption></Filter><Filter label="Drug Has Financials" name="drugHasFinancials" total="2"><FilterOption count="31" label="No"></FilterOption><FilterOption count="23" label="Yes"></FilterOption></Filter><Filter label="Secondary Companies" name="companiesSecondary" total="54"><FilterOption id="28355" count="2" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="22122" count="2" label="Memorial Sloan-Kettering Cancer Center"></FilterOption><FilterOption id="1047486" count="1" label="Adaptimmune Therapeutics plc"></FilterOption><FilterOption id="1007376" count="1" label="Aeras Global TB Vaccine Foundation"></FilterOption><FilterOption id="1015026" count="1" label="AIMM Therapeutics BV"></FilterOption><FilterOption id="1037667" count="1" label="Albireo Ltd"></FilterOption><FilterOption id="27235" count="1" label="Amsterdam Molecular Therapeutics BV"></FilterOption><FilterOption id="1002960" count="1" label="Apoxis SA"></FilterOption><FilterOption id="14343" count="1" label="Avigen Inc"></FilterOption><FilterOption id="14486" count="1" label="Bayer Corp"></FilterOption><FilterOption id="1047464" count="1" label="BioProtection Systems Corp"></FilterOption><FilterOption id="1096601" count="1" label="Cabaret Biotech Ltd"></FilterOption><FilterOption id="15331" count="1" label="Celgene Corp"></FilterOption><FilterOption id="15381" count="1" label="Chiesi Farmaceutici SpA"></FilterOption><FilterOption id="21052" count="1" label="Childrens Hospital of Philadelphia"></FilterOption><FilterOption id="15414" count="1" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1061210" count="1" label="Columbia University Medical Center"></FilterOption><FilterOption id="1049269" count="1" label="Edimer Pharmaceuticals Inc"></FilterOption><FilterOption id="27338" count="1" label="Fondazione Telethon"></FilterOption><FilterOption id="25621" count="1" label="Genzyme General"></FilterOption><FilterOption id="1079441" count="1" label="Ignyta Inc"></FilterOption><FilterOption id="17229" count="1" label="INSERM"></FilterOption><FilterOption id="17269" count="1" label="Ionis Pharmaceuticals Inc"></FilterOption><FilterOption id="17259" count="1" label="Ipsen"></FilterOption><FilterOption id="1039610" count="1" label="IRCCS San Raffaele"></FilterOption><FilterOption id="1090676" count="1" label="Juno Therapeutics Inc"></FilterOption><FilterOption id="23382" count="1" label="MD Anderson Cancer Center"></FilterOption><FilterOption id="18438" count="1" label="Medical Research Council"></FilterOption><FilterOption id="19862" count="1" label="Merck Serono SA"></FilterOption><FilterOption id="1059823" count="1" label="Merck Sharp &amp; Dohme Corp"></FilterOption><FilterOption id="30663" count="1" label="MolMed SpA"></FilterOption><FilterOption id="1039991" count="1" label="Nationwide Children's Hospital"></FilterOption><FilterOption id="1013717" count="1" label="Nerviano Medical Sciences Srl"></FilterOption><FilterOption id="1035966" count="1" label="Neurimmune Therapeutics AG"></FilterOption><FilterOption id="23137" count="1" label="Novartis AG"></FilterOption><FilterOption id="27747" count="1" label="Novimmune SA"></FilterOption><FilterOption id="20649" count="1" label="Ohio State University"></FilterOption><FilterOption id="17580" count="1" label="Ortho-McNeil Inc"></FilterOption><FilterOption id="28066" count="1" label="PTC Therapeutics Inc"></FilterOption><FilterOption id="1042926" count="1" label="Public Health Agency of Canada"></FilterOption><FilterOption id="1005750" count="1" label="San Raffaele Telethon Institute for Gene Therapy"></FilterOption><FilterOption id="16299" count="1" label="Sanofi Genzyme"></FilterOption><FilterOption id="1015871" count="1" label="Shanghai Fosun Pharmaceutical (Group) Co Ltd"></FilterOption><FilterOption id="1089295" count="1" label="Spark Therapeutics LLC"></FilterOption><FilterOption id="21814" count="1" label="St Jude Children's Research Hospital"></FilterOption><FilterOption id="29414" count="1" label="TopoTarget A/S"></FilterOption><FilterOption id="23505" count="1" label="University College London"></FilterOption><FilterOption id="20524" count="1" label="University of Alabama at Birmingham"></FilterOption><FilterOption id="22496" count="1" label="University of Leicester"></FilterOption><FilterOption id="20607" count="1" label="University of London"></FilterOption><FilterOption id="1131627" count="1" label="Vall d'Hebron Research Institute"></FilterOption><FilterOption id="31691" count="1" label="VectorLogics Inc"></FilterOption><FilterOption id="16268" count="1" label="Vifor Pharma Ltd"></FilterOption><FilterOption id="1003156" count="1" label="Vision 7 GmbH"></FilterOption></Filter><Filter label="Primary Indications" name="indicationsPrimary" total="100"><FilterOption id="1828" count="5" label="Multiple myeloma"></FilterOption><FilterOption id="1749" count="4" label="Diffuse large B-cell lymphoma"></FilterOption><FilterOption id="1745" count="4" label="Follicle center lymphoma"></FilterOption><FilterOption id="1734" count="3" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="1228" count="3" label="Factor IX deficiency"></FilterOption><FilterOption id="2454" count="3" label="Glioblastoma"></FilterOption><FilterOption id="319" count="3" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="1729" count="2" label="B-cell acute lymphoblastic leukemia"></FilterOption><FilterOption id="316" count="2" label="B-cell lymphoma"></FilterOption><FilterOption id="2369" count="2" label="Beta thalassemia"></FilterOption><FilterOption id="2367" count="2" label="Enzyme deficiency"></FilterOption><FilterOption id="1108" count="2" label="Glioma"></FilterOption><FilterOption id="616" count="2" label="Graft versus host disease"></FilterOption><FilterOption id="144" count="2" label="Hemolytic uremic syndrome"></FilterOption><FilterOption id="362" count="2" label="Hepatitis D virus infection"></FilterOption><FilterOption id="3665" count="2" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="224" count="2" label="Myocardial infarction"></FilterOption><FilterOption id="2637" count="2" label="Non-alcoholic steatohepatitis"></FilterOption><FilterOption id="1995" count="2" label="Primary biliary cholangitis"></FilterOption><FilterOption id="303" count="2" label="Sickle cell anemia"></FilterOption><FilterOption id="725" count="2" label="Solid tumor"></FilterOption><FilterOption id="727" count="2" label="Spinal muscular atrophy"></FilterOption><FilterOption id="3237" count="1" label="Achromatopsia"></FilterOption><FilterOption id="2997" count="1" label="Acute intermittent porphyria"></FilterOption><FilterOption id="1728" count="1" label="Acute lymphoblastic leukemia"></FilterOption><FilterOption id="1652" count="1" label="Adrenoleukodystrophy"></FilterOption><FilterOption id="3713" count="1" label="Advanced solid tumor"></FilterOption><FilterOption id="1226" count="1" label="Age related macular degeneration"></FilterOption><FilterOption id="2411" count="1" label="Alagille syndrome"></FilterOption><FilterOption id="14" count="1" label="Alzheimers disease"></FilterOption><FilterOption id="2567" count="1" label="Anaplastic astrocytoma"></FilterOption><FilterOption id="1755" count="1" label="Anaplastic large cell lymphoma"></FilterOption><FilterOption id="36" count="1" label="Autoimmune disease"></FilterOption><FilterOption id="548" count="1" label="Autosomal recessive disorder"></FilterOption><FilterOption id="2412" count="1" label="Biliary atresia"></FilterOption><FilterOption id="760" count="1" label="Brain tumor"></FilterOption><FilterOption id="651" count="1" label="Cancer"></FilterOption><FilterOption id="3046" count="1" label="Chikungunya virus infection"></FilterOption><FilterOption id="1765" count="1" label="Cholangiocarcinoma"></FilterOption><FilterOption id="989" count="1" label="Colorectal tumor"></FilterOption><FilterOption id="101" count="1" label="Diabetic neuropathy"></FilterOption><FilterOption id="1049" count="1" label="Ebola virus infection"></FilterOption><FilterOption id="3744" count="1" label="Epidermolysis bullosa dystrophica"></FilterOption><FilterOption id="121" count="1" label="Factor VIII deficiency"></FilterOption><FilterOption id="2034" count="1" label="Glomerular disease"></FilterOption><FilterOption id="135" count="1" label="Glomerulonephritis"></FilterOption><FilterOption id="2035" count="1" label="Goodpasture syndrome"></FilterOption><FilterOption id="141" count="1" label="Guillain Barre syndrome"></FilterOption><FilterOption id="3888" count="1" label="Hematopoietic stem cell transplantation"></FilterOption><FilterOption id="4727" count="1" label="Hemophagocytic lymphohistiocytosis"></FilterOption><FilterOption id="2888" count="1" label="Hepatic porphyria"></FilterOption><FilterOption id="152" count="1" label="Hepatitis B virus infection"></FilterOption><FilterOption id="155" count="1" label="Hepatitis virus infection"></FilterOption><FilterOption id="3542" count="1" label="Hidradenitis suppurativa"></FilterOption><FilterOption id="1751" count="1" label="High grade B-cell lymphoma"></FilterOption><FilterOption id="161" count="1" label="Hodgkins disease"></FilterOption><FilterOption id="170" count="1" label="Huntingtons chorea"></FilterOption><FilterOption id="1822" count="1" label="Hyperoxaluria"></FilterOption><FilterOption id="3076" count="1" label="IgA nephropathy"></FilterOption><FilterOption id="2989" count="1" label="Kidney transplant rejection"></FilterOption><FilterOption id="2784" count="1" label="Laurence-Moon syndrome"></FilterOption><FilterOption id="3595" count="1" label="Leptin deficiency"></FilterOption><FilterOption id="199" count="1" label="Leukemia"></FilterOption><FilterOption id="2447" count="1" label="Liposarcoma"></FilterOption><FilterOption id="755" count="1" label="Lung tumor"></FilterOption><FilterOption id="2404" count="1" label="Lupus nephritis"></FilterOption><FilterOption id="203" count="1" label="Lymphoma"></FilterOption><FilterOption id="1037" count="1" label="Lymphoproliferative disease"></FilterOption><FilterOption id="4898" count="1" label="Major depressive disorder"></FilterOption><FilterOption id="1744" count="1" label="Mantle cell lymphoma"></FilterOption><FilterOption id="3441" count="1" label="Membranous glomerulonephritis"></FilterOption><FilterOption id="3657" count="1" label="Metastatic breast cancer"></FilterOption><FilterOption id="3658" count="1" label="Metastatic colorectal cancer"></FilterOption><FilterOption id="3673" count="1" label="Metastatic head and neck cancer"></FilterOption><FilterOption id="3866" count="1" label="Metastatic ovary cancer"></FilterOption><FilterOption id="3669" count="1" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="221" count="1" label="Mycobacterium tuberculosis infection"></FilterOption><FilterOption id="1272" count="1" label="Myelodysplastic syndrome"></FilterOption><FilterOption id="672" count="1" label="Myopathy"></FilterOption><FilterOption id="1768" count="1" label="Nasopharyngeal carcinoma"></FilterOption><FilterOption id="2726" count="1" label="Neuroblastoma"></FilterOption><FilterOption id="1128" count="1" label="Neuroendocrine tumor"></FilterOption><FilterOption id="1991" count="1" label="Neutropenia"></FilterOption><FilterOption id="2838" count="1" label="Niemann Pick disease type B"></FilterOption><FilterOption id="1262" count="1" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="238" count="1" label="Obesity"></FilterOption><FilterOption id="2498" count="1" label="Osteogenesis imperfecta"></FilterOption><FilterOption id="799" count="1" label="Ovary tumor"></FilterOption><FilterOption id="3530" count="1" label="Post transplant lymphoproliferative disease"></FilterOption><FilterOption id="3514" count="1" label="Postnatal depression"></FilterOption><FilterOption id="1750" count="1" label="Primary mediastinal large B-cell lymphoma"></FilterOption><FilterOption id="2477" count="1" label="Primary sclerosing cholangitis"></FilterOption><FilterOption id="6769" count="1" label="Progressive familial intrahepatic cholestasis"></FilterOption><FilterOption id="279" count="1" label="Pruritus"></FilterOption><FilterOption id="367" count="1" label="Radiation sickness"></FilterOption><FilterOption id="1766" count="1" label="Renal cell carcinoma"></FilterOption><FilterOption id="1024" count="1" label="Reperfusion injury"></FilterOption><FilterOption id="287" count="1" label="Respiratory syncytial virus infection"></FilterOption><FilterOption id="4299" count="1" label="Salivary gland cancer"></FilterOption><FilterOption id="194" count="1" label="Sarcoma"></FilterOption></Filter><Filter label="Secondary Indications" name="indicationsSecondary" total="47"><FilterOption id="651" count="7" label="Cancer"></FilterOption><FilterOption id="188" count="3" label="Inflammatory disease"></FilterOption><FilterOption id="36" count="2" label="Autoimmune disease"></FilterOption><FilterOption id="316" count="2" label="B-cell lymphoma"></FilterOption><FilterOption id="60" count="2" label="Central nervous system disease"></FilterOption><FilterOption id="1734" count="2" label="Chronic lymphocytic leukemia"></FilterOption><FilterOption id="2054" count="2" label="Hematological neoplasm"></FilterOption><FilterOption id="199" count="2" label="Leukemia"></FilterOption><FilterOption id="319" count="2" label="Non-Hodgkin lymphoma"></FilterOption><FilterOption id="114" count="2" label="Sepsis"></FilterOption><FilterOption id="1731" count="1" label="Acute myelogenous leukemia"></FilterOption><FilterOption id="1729" count="1" label="B-cell acute lymphoblastic leukemia"></FilterOption><FilterOption id="93" count="1" label="Depression"></FilterOption><FilterOption id="97" count="1" label="Diabetes mellitus"></FilterOption><FilterOption id="3251" count="1" label="End stage renal disease"></FilterOption><FilterOption id="1011" count="1" label="Esophagus tumor"></FilterOption><FilterOption id="4085" count="1" label="Essential tremor"></FilterOption><FilterOption id="3204" count="1" label="Familial hypercholesterolemia"></FilterOption><FilterOption id="616" count="1" label="Graft versus host disease"></FilterOption><FilterOption id="623" count="1" label="Head and neck tumor"></FilterOption><FilterOption id="142" count="1" label="Hematological disease"></FilterOption><FilterOption id="3791" count="1" label="Hypophosphatasia"></FilterOption><FilterOption id="3771" count="1" label="Idiopathic pulmonary fibrosis"></FilterOption><FilterOption id="3076" count="1" label="IgA nephropathy"></FilterOption><FilterOption id="584" count="1" label="Lipid metabolism disorder"></FilterOption><FilterOption id="201" count="1" label="Liver disease"></FilterOption><FilterOption id="2404" count="1" label="Lupus nephritis"></FilterOption><FilterOption id="6834" count="1" label="Macrophage activation syndrome"></FilterOption><FilterOption id="4898" count="1" label="Major depressive disorder"></FilterOption><FilterOption id="1744" count="1" label="Mantle cell lymphoma"></FilterOption><FilterOption id="205" count="1" label="Melanoma"></FilterOption><FilterOption id="655" count="1" label="Metabolic disorder"></FilterOption><FilterOption id="3294" count="1" label="Metabolic syndrome X"></FilterOption><FilterOption id="224" count="1" label="Myocardial infarction"></FilterOption><FilterOption id="1295" count="1" label="Neuropathic pain"></FilterOption><FilterOption id="236" count="1" label="Niemann Pick disease"></FilterOption><FilterOption id="837" count="1" label="Non-insulin dependent diabetes"></FilterOption><FilterOption id="799" count="1" label="Ovary tumor"></FilterOption><FilterOption id="2549" count="1" label="Postmenopausal osteoporosis"></FilterOption><FilterOption id="2890" count="1" label="Prader-Willi syndrome"></FilterOption><FilterOption id="367" count="1" label="Radiation sickness"></FilterOption><FilterOption id="725" count="1" label="Solid tumor"></FilterOption><FilterOption id="3034" count="1" label="Status epilepticus"></FilterOption><FilterOption id="65" count="1" label="Stroke"></FilterOption><FilterOption id="1585" count="1" label="Syndrome X"></FilterOption><FilterOption id="1133" count="1" label="Thrombocytopenic purpura"></FilterOption><FilterOption id="515" count="1" label="Transplant rejection"></FilterOption></Filter><Filter label="Regulatory Designations" name="drugRegulatoryDesignations" total="12"><FilterOption id="10" count="54" label="PRIME"></FilterOption><FilterOption id="1" count="46" label="Orphan Drug"></FilterOption><FilterOption id="3" count="33" label="Breakthrough Therapy"></FilterOption><FilterOption id="2" count="22" label="Fast Track"></FilterOption><FilterOption id="9" count="12" label="Paediatric Investigation Plan"></FilterOption><FilterOption id="13" count="10" label="Rare Pediatric Disease"></FilterOption><FilterOption id="11" count="7" label="Priority Review"></FilterOption><FilterOption id="5" count="6" label="Accelerated Approval"></FilterOption><FilterOption id="17" count="4" label="Regenerative Medicine Advanced Therapy"></FilterOption><FilterOption id="14" count="4" label="Sakigake"></FilterOption><FilterOption id="16" count="2" label="Promising Innovative Medicine"></FilterOption><FilterOption id="4" count="1" label="Advanced Therapy Medicinal Product"></FilterOption></Filter><Filter label="Primary Actions" name="actionsPrimary" total="51"><FilterOption id="5080" count="4" label="B-lymphocyte antigen CD19 modulator"></FilterOption><FilterOption id="8255" count="3" label="APRIL receptor modulator"></FilterOption><FilterOption id="56072" count="3" label="F9 gene stimulator"></FilterOption><FilterOption id="1773" count="2" label="Factor IX modulator"></FilterOption><FilterOption id="15460" count="2" label="HBB gene stimulator"></FilterOption><FilterOption id="72084" count="1" label="5 Aminolevulinate synthase 1 inhibitor"></FilterOption><FilterOption id="17788" count="1" label="ABCD1 gene stimulator"></FilterOption><FilterOption id="3736" count="1" label="Anaplastic lymphoma kinase receptor inhibitor"></FilterOption><FilterOption id="7343" count="1" label="Beta amyloid antagonist"></FilterOption><FilterOption id="50096" count="1" label="Cancer testis antigen NY-ESO-1 modulator"></FilterOption><FilterOption id="5322" count="1" label="CD79b antagonist"></FilterOption><FilterOption id="5367" count="1" label="CD95 antagonist"></FilterOption><FilterOption id="18219" count="1" label="CDA gene stimulator"></FilterOption><FilterOption id="38488" count="1" label="CNGB3 gene stimulator"></FilterOption><FilterOption id="18396" count="1" label="COL7A1 gene stimulator"></FilterOption><FilterOption id="127" count="1" label="Complement C5a receptor antagonist"></FilterOption><FilterOption id="973" count="1" label="Complement cascade inhibitor"></FilterOption><FilterOption id="2688" count="1" label="Cysteine protease stimulator"></FilterOption><FilterOption id="9272" count="1" label="Cytosine deaminase inhibitor"></FilterOption><FilterOption id="23792" count="1" label="Ectodysplasin A ligand"></FilterOption><FilterOption id="73728" count="1" label="F8 gene stimulator"></FilterOption><FilterOption id="1199" count="1" label="GABA A receptor modulator"></FilterOption><FilterOption id="191" count="1" label="Glycine partial agonist"></FilterOption><FilterOption id="18854" count="1" label="Hemoglobin alpha subunit modulator"></FilterOption><FilterOption id="19115" count="1" label="HLA class I antigen A-2 alpha modulator"></FilterOption><FilterOption id="15971" count="1" label="HTT gene inhibitor"></FilterOption><FilterOption id="90388" count="1" label="Hydroxyacid oxidase 1 modulator"></FilterOption><FilterOption id="13148" count="1" label="Ileal sodium bile acid cotransporter inhibitor"></FilterOption><FilterOption id="5739" count="1" label="Immunoglobulin G antagonist"></FilterOption><FilterOption id="1919" count="1" label="Insulin sensitizer"></FilterOption><FilterOption id="5860" count="1" label="Integrin alpha-5/beta-3 modulator"></FilterOption><FilterOption id="5866" count="1" label="Integrin alpha-5/beta-5 modulator"></FilterOption><FilterOption id="51202" count="1" label="Interferon gamma ligand inhibitor"></FilterOption><FilterOption id="3021" count="1" label="Leptin receptor modulator"></FilterOption><FilterOption id="11739" count="1" label="Mannan-binding lectin serine protease-2 inhibitor"></FilterOption><FilterOption id="2446" count="1" label="Melanocortin MC4 receptor agonist"></FilterOption><FilterOption id="72230" count="1" label="MTM1 gene stimulator"></FilterOption><FilterOption id="72227" count="1" label="Myotubularin stimulator"></FilterOption><FilterOption id="1820" count="1" label="NMDA receptor modulator"></FilterOption><FilterOption id="282" count="1" label="NMDA receptor partial agonist"></FilterOption><FilterOption id="3971" count="1" label="PPAR delta agonist"></FilterOption><FilterOption id="1875" count="1" label="Protein farnesyltransferase inhibitor"></FilterOption><FilterOption id="3826" count="1" label="Ros1 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="16646" count="1" label="Sclerostin inhibitor"></FilterOption><FilterOption id="16360" count="1" label="SMN1 gene stimulator"></FilterOption><FilterOption id="51969" count="1" label="Sphingomyelin phosphodiesterase stimulator"></FilterOption><FilterOption id="34226" count="1" label="Thymidine kinase 2 stimulator"></FilterOption><FilterOption id="54427" count="1" label="TREM receptor 1 antagonist"></FilterOption><FilterOption id="3840" count="1" label="TrkA receptor antagonist"></FilterOption><FilterOption id="3842" count="1" label="TrkB receptor antagonist"></FilterOption><FilterOption id="3844" count="1" label="TrkC receptor antagonist"></FilterOption></Filter><Filter label="Primary Companies" name="companiesPrimary" total="68"><FilterOption id="16284" count="3" label="bluebird bio Inc"></FilterOption><FilterOption id="15414" count="3" label="Chugai Pharmaceutical Co Ltd"></FilterOption><FilterOption id="19446" count="3" label="Roche Holding AG"></FilterOption><FilterOption id="29927" count="2" label="Alnylam Pharmaceuticals Inc"></FilterOption><FilterOption id="15331" count="2" label="Celgene Corp"></FilterOption><FilterOption id="28355" count="2" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="29943" count="2" label="Medison Pharma Ltd"></FilterOption><FilterOption id="1053899" count="1" label="Abramson Cancer Center of the University of Pennsylvania"></FilterOption><FilterOption id="1015309" count="1" label="Albireo Pharma Inc"></FilterOption><FilterOption id="1088700" count="1" label="Allergan plc"></FilterOption><FilterOption id="1033114" count="1" label="Apogenix GmbH"></FilterOption><FilterOption id="1143621" count="1" label="ApolloBio Corp"></FilterOption><FilterOption id="1074591" count="1" label="Atara Biotherapeutics Inc"></FilterOption><FilterOption id="1086349" count="1" label="Audentes Therapeutics Inc"></FilterOption><FilterOption id="1086634" count="1" label="AveXis Inc"></FilterOption><FilterOption id="1077737" count="1" label="Biofabri SL"></FilterOption><FilterOption id="1005244" count="1" label="Biogen Inc"></FilterOption><FilterOption id="25861" count="1" label="BioMarin Pharmaceutical Inc"></FilterOption><FilterOption id="1088011" count="1" label="CANbridge Life Sciences Ltd"></FilterOption><FilterOption id="28458" count="1" label="ChemoCentryx Inc"></FilterOption><FilterOption id="1061210" count="1" label="Columbia University Medical Center"></FilterOption><FilterOption id="18199" count="1" label="CymaBay Therapeutics Inc"></FilterOption><FilterOption id="1017506" count="1" label="Daiichi Sankyo Co Ltd"></FilterOption><FilterOption id="15615" count="1" label="Dana-Farber Cancer Institute Inc"></FilterOption><FilterOption id="1181247" count="1" label="Dermelix LLC"></FilterOption><FilterOption id="1063679" count="1" label="DNAtrix Inc"></FilterOption><FilterOption id="1045741" count="1" label="Eiger BioPharmaceuticals Inc"></FilterOption><FilterOption id="15872" count="1" label="Eisai Co Ltd"></FilterOption><FilterOption id="1081667" count="1" label="EspeRare Foundation"></FilterOption><FilterOption id="1181265" count="1" label="Fosun Kite"></FilterOption><FilterOption id="1122587" count="1" label="Freeline Therapeutics"></FilterOption><FilterOption id="19453" count="1" label="Genentech Inc"></FilterOption><FilterOption id="1079834" count="1" label="Global Blood Therapeutics Inc"></FilterOption><FilterOption id="29434" count="1" label="Hansa Biopharma AB"></FilterOption><FilterOption id="1068819" count="1" label="Hepatera LLC"></FilterOption><FilterOption id="1094088" count="1" label="Inotrem SA"></FilterOption><FilterOption id="1014416" count="1" label="International AIDS Vaccine Initiative"></FilterOption><FilterOption id="26997" count="1" label="Janssen Biotech Inc"></FilterOption><FilterOption id="1090676" count="1" label="Juno Therapeutics Inc"></FilterOption><FilterOption id="17665" count="1" label="Kissei Pharmaceutical Co Ltd"></FilterOption><FilterOption id="1056870" count="1" label="Kite Pharma Inc"></FilterOption><FilterOption id="1153065" count="1" label="Krystal Biotech Inc"></FilterOption><FilterOption id="18008" count="1" label="MedImmune LLC"></FilterOption><FilterOption id="1108651" count="1" label="MeiraGTx"></FilterOption><FilterOption id="18077" count="1" label="Merck &amp; Co Inc"></FilterOption><FilterOption id="1112149" count="1" label="Mereo BioPharma Group Ltd"></FilterOption><FilterOption id="1172389" count="1" label="Modis Therapeutics Inc"></FilterOption><FilterOption id="1067095" count="1" label="MYR GmbH"></FilterOption><FilterOption id="1143778" count="1" label="Nanjing Legend Biotech Co Ltd"></FilterOption><FilterOption id="29216" count="1" label="Naurex Inc"></FilterOption><FilterOption id="1117012" count="1" label="Nohla Therapeutics Inc"></FilterOption><FilterOption id="23137" count="1" label="Novartis AG"></FilterOption><FilterOption id="23867" count="1" label="Omeros Corp"></FilterOption><FilterOption id="1123260" count="1" label="Orchard Therapeutics Ltd"></FilterOption><FilterOption id="18767" count="1" label="Pfizer Inc"></FilterOption><FilterOption id="1100559" count="1" label="Rhythm Pharmaceuticals Inc"></FilterOption><FilterOption id="1065589" count="1" label="SAGE Therapeutics Inc"></FilterOption><FilterOption id="16299" count="1" label="Sanofi Genzyme"></FilterOption><FilterOption id="22127" count="1" label="Sanofi Pasteur"></FilterOption><FilterOption id="21814" count="1" label="St Jude Children's Research Hospital"></FilterOption><FilterOption id="28921" count="1" label="Swedish Orphan Biovitrum AB"></FilterOption><FilterOption id="26988" count="1" label="Takeda Vaccines Inc"></FilterOption><FilterOption id="1066948" count="1" label="Themis Bioscience GmbH"></FilterOption><FilterOption id="1051749" count="1" label="Tocagen Inc"></FilterOption><FilterOption id="1068190" count="1" label="uniQure BV"></FilterOption><FilterOption id="25210" count="1" label="Universidad de Zaragoza"></FilterOption><FilterOption id="28348" count="1" label="University of Heidelberg"></FilterOption><FilterOption id="1058402" count="1" label="Vifor-Fresenius Medical Care Renal Pharma Ltd"></FilterOption></Filter><Filter label="Highest Phase" name="phaseHighest" total="9"><FilterOption id="C3" count="21" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="17" label="Phase 2 Clinical"></FilterOption><FilterOption id="L" count="5" label="Launched"></FilterOption><FilterOption id="PR" count="3" label="Pre-registration"></FilterOption><FilterOption id="R" count="3" label="Registered"></FilterOption><FilterOption id="DR" count="2" label="Discovery"></FilterOption><FilterOption id="DX" count="1" label="Discontinued"></FilterOption><FilterOption id="CU" count="1" label="Clinical"></FilterOption><FilterOption id="C1" count="1" label="Phase 1 Clinical"></FilterOption></Filter></Filters></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugResultsOutput>